On November 17, 2026 Intryx Therapeutics, LLC (formerly known as NanOlogy, LLC) ("Intryx"), a clinical-stage oncology company leading the development of intratumoral cancer therapeutics enabled by its Purcision Platform Technology, reported the U.S. Food and Drug Administration clearance of an investigational new drug (IND) application for ITX-402 in brain neoplasms. The company plans to initiate TIGER-1, a Phase 1/2a pediatric clinical trial, to evaluate ITX-402 in diffuse midline glioma (DMG) including diffuse intrinsic pontine glioma (DIPG).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ITX-402 is a large surface area microparticle (LSAM) of cisplatin, a proven therapeutic, in suspension for stereotactic intratumoral delivery to brain tumors resulting in continuous concentrated local drug release over time.
The open-label dose-escalating Phase 1/2a single-arm trial (NCT07767110), titled Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response (TIGER-1), is designed to enroll up to 20 patients to evaluate safety, drug exposure, and clinical activity of ITX-402 in patients with confirmed DMG/DIPG following standard-of-care therapy.
"IND clearance of ITX-402 marks an important achievement in the fight against DMG/DIPG, one of the most challenging pediatric cancers to treat," said Intryx Chief Executive Officer David Arthur. "Our preclinical research demonstrated drug activity in DMG/DIPG models and the feasibility and safety of injecting ITX-402 into precise areas of the brain. We look forward to initiating this trial and the possibility of a new therapeutic option for children with this devastating disease."
Intryx is collaborating with WEP Clinical, Morrisville NC, as its clinical research organization to conduct the TIGER-1 clinical trial.
About Diffuse Midline Glioma including Diffuse Intrinsic Pontine Glioma
DMG/DIPG is a highly lethal inoperable brain tumor that afflicts approximately 350 children and their families each year in the United States. Median survival is less than one year and fewer than 2% of patients survive five years. Current treatment options including radiotherapy and dordaviprone offer limited benefits and a significant unmet need exists for newer therapies to improve quality of life and survival.
About Purcision Platform Technology
Purcision converts small molecules into large surface area microparticles (LSAMs) optimized for intratumoral delivery aimed at increasing solid tumor response without increasing systemic toxicity. LSAMs are comprised of 100% pure drug, with no excipients or coating agents, and feature a particle size designed for tumor retention, increased surface area for continuous concentrated local drug release over time, and reduced bulk density for homogeneity in suspension at time of use. Each new LSAM offers composition-of-matter patentability protecting these key regulatory specifications.
(Press release, Intryx Therapeutics, NOV 17, 2026, View Source [SID1234674857])